The landscape of myeloma treatment is on the brink of an innovative overhaul as the potential of on-body delivery of Isatuximab garners burgeoning attention. The excitement is driven by the recent FDA approvals that underscore the effectiveness of anti-CD38 therapies in the treatment of newly diagnosed multiple myeloma patients. The regimens’ efficacy, coupled with the […]
